These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31899974)

  • 1.
    Parish T
    Expert Opin Drug Discov; 2020 Mar; 15(3):349-358. PubMed ID: 31899974
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
    Christophe T; Ewann F; Jeon HK; Cechetto J; Brodin P
    Future Med Chem; 2010 Aug; 2(8):1283-93. PubMed ID: 21426019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery.
    Mukherjee R; Chandra Pal A; Banerjee M
    Tuberculosis (Edinb); 2017 Sep; 106():44-52. PubMed ID: 28802404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current challenges in drug discovery for tuberculosis.
    Kumar A; Chettiar S; Parish T
    Expert Opin Drug Discov; 2017 Jan; 12(1):1-4. PubMed ID: 27797593
    [No Abstract]   [Full Text] [Related]  

  • 7. The relevance of persisters in tuberculosis drug discovery.
    Mandal S; Njikan S; Kumar A; Early JV; Parish T
    Microbiology (Reading); 2019 May; 165(5):492-499. PubMed ID: 30775961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium tuberculosis High-Throughput Screening.
    White EL; Tower NA; Rasmussen L
    Methods Mol Biol; 2016; 1439():181-95. PubMed ID: 27316996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis.
    Gold B; Warrier T; Nathan C
    Methods Mol Biol; 2015; 1285():293-315. PubMed ID: 25779324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis.
    Manning AJ; Ovechkina Y; McGillivray A; Flint L; Roberts DM; Parish T
    Methods; 2017 Aug; 127():3-11. PubMed ID: 28366666
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Sawicki R; Ginalska G
    Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
    Dhiman R; Singh R
    IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host-pathogen systems for early drug discovery against tuberculosis.
    Trofimov V; Costa-Gouveia J; Hoffmann E; Brodin P
    Curr Opin Microbiol; 2017 Oct; 39():143-151. PubMed ID: 29179041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis.
    Gold B; Warrier T; Nathan C
    Methods Mol Biol; 2021; 2314():611-635. PubMed ID: 34235673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
    Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
    Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose-Response Relationship Using Intracellular Pharmacodynamic Modeling (PD
    Donnellan S; Martínez-Rodríguez C; Aljayyoussi G; Biagini GA
    Methods Mol Biol; 2021; 2296():393-408. PubMed ID: 33977461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.
    Bonnett SA; Dennison D; Files M; Bajpai A; Parish T
    PLoS One; 2018; 13(10):e0198059. PubMed ID: 30332412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.